Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Adagrasib dose of twice daily · 1 trial · 2 indications
Defined as the percent of patients documented to have a confirmed CR or PR
PFS is defined as time from first study treatment until disease progression or death from any cause, whichever occurs first.
| Arm | Type | Description |
|---|---|---|
| Cohort A: PD-L1 TPS≥ 1% (Closed) | EXPERIMENTAL | Adagrasib 400 mg BID for 2 cycles followed by adagrasib 400 mg BID + pembrolizumab 200 mg every 3 weeks (Q3W) up to 35 cycles |
| Cohort C | EXPERIMENTAL | Adagrasib 400 mg BID + pemetrexed 500 mg/m2 Q3W + pembrolizumab 200 mg Q3W up to 31 cycles |
| Cohort E | EXPERIMENTAL | Adagrasib 400 mg BID + pembrolizumab 200 mg Q3W + pemetrexed 500 mg/m2 + cisplatin 75 mg/m2 Q3W OR carboplatin AUC 5 Q3W for 4 cycles, followed by adagrasib 400 mg BID + pemetrexed 500 mg/m2 Q3W + pembrolizumab 200 mg Q3W (up to 31 cycles) |
| Name | Type | Description |
|---|---|---|
| Adagrasib oral dose of 400 mg twice daily tablets | DRUG | oral dose of 400 mg twice daily tablets |
| Pembrolizumab | COMBINATION_PRODUCT | IV infusion once every 3 weeks |
| Chemotherapy: Pemetrexed | COMBINATION_PRODUCT | IV infusion once every 3 weeks |
| Cisplatin/Carboplatin | COMBINATION_PRODUCT | IV infusion once every 3 weeks |
Cohort A\* (closed): Has an untreated and unresectable or metastatic NSCLC with histologically confirmed (squamous or nonsquamous) KRASG12C mutation and histologically confirmed PD-L1 TPS ≥1%. * Cohort C: Has an untreated and unresectable or metastatic NSCLC with histologically confirmed (non-squam...
Adagrasib is an investigational small molecule being studied for the treatment of advanced non-small cell lung cancer (NSCLC). It is administered orally at a dose of 400 mg twice daily. The drug is currently in Phase 2 clinical development for this indication.
Adagrasib targets the KRAS G12C mutation, a specific genetic alteration found in some cancers. The ongoing clinical trial specifically enrolls patients with advanced NSCLC who have this KRAS G12C mutation, indicating the drug's mechanism is directed at this mutated form of the KRAS protein.
Adagrasib is being developed by Bristol-Myers Squibb Company, a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol BMY. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with advanced NSCLC.
Adagrasib is currently in Phase 2 clinical development. It is an investigational drug, meaning it has not yet been approved by regulatory authorities. The ongoing Phase 2 trial is active but not recruiting participants, and it is designed to evaluate combination therapies with adagrasib in advanced NSCLC.
Adagrasib is being studied in a Phase 2 clinical trial with the identifier NCT05609578. This trial, titled 'Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation,' is active but not recruiting. It enrolls approximately 90 participants across multiple countries, including the United States, France, Greece, Hungary, Italy, Poland, and Spain.
Yes, Adagrasib is the same as the drug referred to as 'Adagrasib oral dose of 400 mg twice daily tablets.' The drug is administered orally at a dose of 400 mg twice daily, and this formulation is being evaluated in clinical trials for advanced NSCLC.